Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Hanx Biopharmaceuticals (Wuhan) Co EPS (Diluted) Related Terms
Hanx Biopharmaceuticals (Wuhan) Co EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hanx Biopharmaceuticals (Wuhan) Co EPS (Diluted) Chart
Hanx Biopharmaceuticals (Wuhan) Co Annual Data
Trend
Dec23
Dec24
Dec25
EPS (Diluted)
-0.61
-0.91
-1.23
Hanx Biopharmaceuticals (Wuhan) Co Semi-Annual Data
Dec23
Dec24
Dec25
EPS (Diluted)
-0.61
-0.91
-1.23
HKSE:03378 vs VRTX, REGN, RVMD: EPS (Diluted) Comparison
For the Biotechnology subindustry, Hanx Biopharmaceuticals (Wuhan) Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hanx Biopharmaceuticals (Wuhan) Co PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hanx Biopharmaceuticals (Wuhan) Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Hanx Biopharmaceuticals (Wuhan) Co's PE Ratio falls into.
Hanx Biopharmaceuticals (Wuhan) Co EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a EPS (Diluted) of HK$ as of Dec. 2025. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors.
Is Hanx Biopharmaceuticals (Wuhan) Co's EPS (Diluted) too high?
Hanx Biopharmaceuticals (Wuhan) Co's current EPS (Diluted) is HK$. Overall, Hanx Biopharmaceuticals (Wuhan) Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hanx Biopharmaceuticals (Wuhan) Co's EPS (Diluted) compare to VRTX and REGN?
Hanx Biopharmaceuticals (Wuhan) Co's EPS (Diluted) of HK$ can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Biotechnology company?
A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. Hanx Biopharmaceuticals (Wuhan) Co's current EPS (Diluted) is HK$. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hanx Biopharmaceuticals (Wuhan) Co stock overvalued right now?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a current EPS (Diluted) of HK$. The current EPS (Diluted) is HK$. Hanx Biopharmaceuticals (Wuhan) Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378), the current EPS (Diluted) is HK$ as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hanx Biopharmaceuticals (Wuhan) Co Business Description
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
11GF Score
Get the complete analysis for HKSE:03378
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03378 has been successfully added to your 
